Rocket Pharmaceuticals (RCKT) Competitors

Rocket Pharmaceuticals logo
$9.86 -0.02 (-0.20%)
Closing price 02/12/2025 04:00 PM Eastern
Extended Trading
$9.87 +0.01 (+0.10%)
As of 02/12/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RCKT vs. SRRK, AKRO, ACLX, RYTM, APLS, CRNX, VKTX, IMVT, ACAD, and MTSR

Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Scholar Rock (SRRK), Akero Therapeutics (AKRO), Arcellx (ACLX), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), Crinetics Pharmaceuticals (CRNX), Viking Therapeutics (VKTX), Immunovant (IMVT), ACADIA Pharmaceuticals (ACAD), and Metsera (MTSR). These companies are all part of the "pharmaceutical products" industry.

Rocket Pharmaceuticals vs.

Scholar Rock (NASDAQ:SRRK) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.

Scholar Rock presently has a consensus price target of $40.43, indicating a potential upside of 8.71%. Rocket Pharmaceuticals has a consensus price target of $47.27, indicating a potential upside of 379.44%. Given Rocket Pharmaceuticals' higher possible upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Scholar Rock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Scholar Rock
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.14
Rocket Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.92

Rocket Pharmaceuticals received 224 more outperform votes than Scholar Rock when rated by MarketBeat users. Likewise, 73.22% of users gave Rocket Pharmaceuticals an outperform vote while only 66.01% of users gave Scholar Rock an outperform vote.

CompanyUnderperformOutperform
Scholar RockOutperform Votes
167
66.01%
Underperform Votes
86
33.99%
Rocket PharmaceuticalsOutperform Votes
391
73.22%
Underperform Votes
143
26.78%

Scholar Rock has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500.

Rocket Pharmaceuticals' return on equity of -62.62% beat Scholar Rock's return on equity.

Company Net Margins Return on Equity Return on Assets
Scholar RockN/A -145.60% -91.83%
Rocket Pharmaceuticals N/A -62.62%-54.17%

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are held by institutional investors. 19.2% of Scholar Rock shares are held by company insiders. Comparatively, 28.5% of Rocket Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Rocket Pharmaceuticals had 2 more articles in the media than Scholar Rock. MarketBeat recorded 5 mentions for Rocket Pharmaceuticals and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 1.58 beat Rocket Pharmaceuticals' score of 0.66 indicating that Scholar Rock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Scholar Rock
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Rocket Pharmaceuticals
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Scholar Rock has higher revenue and earnings than Rocket Pharmaceuticals. Scholar Rock is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scholar Rock$33.19M104.89-$165.79M-$2.35-15.83
Rocket PharmaceuticalsN/AN/A-$245.60M-$2.75-3.59

Summary

Rocket Pharmaceuticals beats Scholar Rock on 11 of the 17 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RCKT vs. The Competition

MetricRocket PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$898.84M$6.89B$5.66B$9.04B
Dividend YieldN/A2.90%5.31%4.00%
P/E Ratio-3.599.6390.3619.28
Price / SalesN/A312.201,035.7379.82
Price / CashN/A75.4646.0938.87
Price / Book1.815.535.135.00
Net Income-$245.60M$123.50M$113.24M$222.75M
7 Day Performance-12.28%-4.00%-0.99%-0.57%
1 Month Performance-11.49%-1.51%4.19%3.00%
1 Year Performance-67.12%2.27%21.68%17.85%

Rocket Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RCKT
Rocket Pharmaceuticals
4.7867 of 5 stars
$9.86
-0.2%
$47.27
+379.4%
-67.1%$898.84MN/A-3.59240
SRRK
Scholar Rock
3.4029 of 5 stars
$39.00
-2.4%
$40.43
+3.7%
+136.1%$3.63B$33.19M-16.51140Positive News
Gap Down
AKRO
Akero Therapeutics
4.4882 of 5 stars
$51.98
-4.1%
$75.86
+45.9%
+126.0%$3.62BN/A-13.8330Insider Trade
Short Interest ↑
Gap Up
ACLX
Arcellx
1.525 of 5 stars
$66.43
-0.7%
$105.93
+59.5%
-2.0%$3.59B$110.32M-93.4880Short Interest ↑
Gap Down
RYTM
Rhythm Pharmaceuticals
4.0339 of 5 stars
$58.18
-1.7%
$68.09
+17.0%
+9.9%$3.57B$77.43M-13.42140Insider Trade
Analyst Revision
Gap Down
APLS
Apellis Pharmaceuticals
4.2437 of 5 stars
$28.68
-2.4%
$46.71
+62.9%
-57.9%$3.57B$396.59M-14.13770Short Interest ↓
Gap Down
CRNX
Crinetics Pharmaceuticals
4.2771 of 5 stars
$36.94
-0.1%
$72.64
+96.6%
-10.4%$3.42B$4.01M-9.89210Analyst Forecast
Gap Down
VKTX
Viking Therapeutics
4.4333 of 5 stars
$30.43
-6.6%
$96.92
+218.5%
-7.6%$3.39BN/A-30.4420Short Interest ↑
Analyst Revision
IMVT
Immunovant
2.6355 of 5 stars
$19.75
-3.2%
$46.73
+136.6%
-47.6%$3.35BN/A-7.54120Earnings Report
Analyst Forecast
Analyst Revision
ACAD
ACADIA Pharmaceuticals
3.8167 of 5 stars
$18.90
+1.9%
$24.13
+27.7%
-28.6%$3.14B$929.24M24.22510Analyst Forecast
Short Interest ↓
MTSR
Metsera
N/A$29.81
+1.1%
N/AN/A$3.07BN/A0.0081

Related Companies and Tools


This page (NASDAQ:RCKT) was last updated on 2/13/2025 by MarketBeat.com Staff
From Our Partners